Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price

 
• By Ian Schofield
  
SC1711_Purse-Pills_673872868_1200
Leadiant is accused of charging too much for its CTX drug

More from Pricing Debate

More from Market Access